APT THERAPEUTICS, INC.

Basic Information

4041 Forest Park Avenue
SAINT LOUIS, MO, 63108-3213

Company Profile

n/a

Additional Details

Field Value
DUNS: 192266141
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Manufacturing of Growth Factors to Enable Cardiopoietic Stem Cell Therapy for Hea

    Amount: $224,139.00

    DESCRIPTION (provided by applicant): Cardiopoietic cell therapy significantly improved left ventricular function, blunted pathological remodeling, and functional outcomes in animal models and Phase I/ ...

    SBIR Phase I 2014 Department of Health and Human Services
  2. Low-dose IL2-based Immunomodulatory therapy for Stroke

    Amount: $224,879.00

    DESCRIPTION (provided by applicant): It has been recently shown that CD4+ and CD8+ T lymphocytes are critically involved in the collateral brain injury and neurological deficit associated with experim ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Magnetic Flow Sorter for Pancreatic Islet Isolation

    Amount: $288,298.00

    DESCRIPTION (provided by applicant): Bone metastasis is common in patients with advanced breast, prostate, and lung cancers as these tumors have a remarkable ability to metastasize to bone. Two-thirds ...

    SBIR Phase I 2013 Department of Health and Human Services
  4. Adjunctive Use of Apyrase to Fibrinolytic Therapy

    Amount: $1,307,456.00

    DESCRIPTION (provided by applicant): Acute myocardial infarction is the leading cause of death in most industrialized nations. The estimated annual incidence in the US is 865,000 events, with ST-segm ...

    SBIR Phase II 2012 Department of Health and Human Services
  5. Prevention of Vein Graft Intimal Hyperplasia with Optimized Human Apyrase

    Amount: $281,598.00

    DESCRIPTION (provided by applicant): The saphenous vein is the most commonly used graft for coronary artery bypass and peripheral bypass surgery, but has poor patency. 15-20% grafts fail in the first ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. Combination Treatment of tPA and Apyrase for Stroke

    Amount: $1,107,154.00

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for ...

    SBIR Phase II 2010 Department of Health and Human Services
  7. Combination Therapy of Aspirin and Apyrase for Stroke

    Amount: $287,622.00

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for acute ischemic stroke which is a leading cause of death and disability with almost no effective therapy for ...

    SBIR Phase I 2010 Department of Health and Human Services
  8. Adjunctive Use of Apyrase to Fibrinolytic Therapy

    Amount: $226,120.00

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for treatment of acute myocardial infarction. This enzyme strongly inhibits platelet activation and aggregation ...

    SBIR Phase I 2009 Department of Health and Human Services
  9. Apyrase to treat ischemia/reperfusion injury during lung transplantation

    Amount: $839,863.00

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy to prevent or reduce ischemia-reperfusion injury during lung transplantation. The enzyme strongly preserves vas ...

    SBIR Phase II 2009 Department of Health and Human Services
  10. Human Apyrase to Disrupt Cancer Therapy

    Amount: $196,745.00

    DESCRIPTION (provided by applicant): Human apyrase represents a highly promising therapy for inhibition of cancer metastasis. The enzyme strongly inhibits platelet activation and aggregation without i ...

    SBIR Phase I 2008 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government